2023
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Foldi J, Tsagianni A, Salganik M, Schnabel C, Brufsky A, van Londen G, Pusztai L, Sanft T. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. BMC Cancer 2023, 23: 606. PMID: 37391697, PMCID: PMC10314405, DOI: 10.1186/s12885-023-11104-w.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine therapyEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerEndocrine therapyBreast cancerLate breast cancer recurrenceExtended endocrine therapyNon-persistence ratesIntolerable side effectsBone density scanBreast cancer recurrenceHigher likelihoodRate of persistenceElectronic health recordsConclusionsIn patientsMedication persistenceTreatment persistenceLow patientsMetastatic recurrenceCancer recurrenceCommon reasonSide effectsPatientsStage IRekindling Joy in Medicine Through Thoughtful Communication: A Practical Guide.
Sanft T, Winer E. Rekindling Joy in Medicine Through Thoughtful Communication: A Practical Guide. American Society Of Clinical Oncology Educational Book 2023, 43: e100034. PMID: 37267275, DOI: 10.1200/edbk_100034.Peer-Reviewed Original ResearchThe brown university cancer prevention and survivorship curriculum: A case study on program development in an internal medicine residency.
Francis E, Pounardjian T, Li J, Moku P, Avidan O, DeCarli K, Manzullo E, Sanft T, McGarry K, Dizon D, Duffy C. The brown university cancer prevention and survivorship curriculum: A case study on program development in an internal medicine residency. Journal Of Clinical Oncology 2023, 41: 11031-11031. DOI: 10.1200/jco.2023.41.16_suppl.11031.Peer-Reviewed Original ResearchCancer preventionCancer survivorsIM residentsEarly detectionMedicine residentsCancer care continuumQuality of lifeCancer control continuumClinical skillsHematology-oncology fellowsInternal medicine residency programsInternal medicine residentsSecondary preventionInternal medicine residencySurvivorship experienceMedicine residency programsProvider teamCare continuumLong-term effectsClinical experienceOncology fellowsHealth disparitiesPatientsPreventative servicesPreventionPartnering With Patients and Caregivers in Cancer Care: Lessons From Experiences With Transgender, Hispanic, and Pediatric Populations.
Katz N, Alpert A, Aristizabal M, McDaniels-Davidson C, Sacks B, Sanft T, Chou C, Martinez M. Partnering With Patients and Caregivers in Cancer Care: Lessons From Experiences With Transgender, Hispanic, and Pediatric Populations. American Society Of Clinical Oncology Educational Book 2023, 43: e397264. PMID: 37200592, DOI: 10.1200/edbk_397264.Peer-Reviewed Original ResearchConceptsPediatric populationOncology careFamily-centered careQuality of carePatient populationCancer careCancer morbidityOncology cliniciansClinical trialsEffective patientPatientsCare provisionCancer diagnosisCareHealth careCaregiversCertain populationsUnequal burdenResearch participationCliniciansInequitable accessIndividual needsPopulationMorbidityMortalityAntibiotic therapy is associated with adverse drug events among older adults with advanced cancer: A cohort study
Datta R, Han L, Doyle M, Allore H, Sanft T, Quagliarello V, Juthani-Mehta M. Antibiotic therapy is associated with adverse drug events among older adults with advanced cancer: A cohort study. Palliative Medicine 2023, 37: 793-798. PMID: 36999898, DOI: 10.1177/02692163231162889.Peer-Reviewed Original ResearchConceptsAdverse drug eventsAntibiotic therapyDrug eventsAdvanced cancerOlder adultsIndex admissionPalliative chemotherapyCohort studyTertiary care centerHospitalized older adultsPalliative care providersMultidrug-resistant organismsMean ageCommon tumorsCare centerCare providersRatio of daysSolid tumorsMultivariable testingPatientsTherapyStandardized criteriaCancerMean timeAdults
2022
Engaging TEAM Medicine in Patient Care: Redefining Cancer Survivorship From Diagnosis.
Alfano CM, Oeffinger K, Sanft T, Tortorella B. Engaging TEAM Medicine in Patient Care: Redefining Cancer Survivorship From Diagnosis. American Society Of Clinical Oncology Educational Book 2022, 42: 1-11. PMID: 35649204, DOI: 10.1200/edbk_349391.Peer-Reviewed Original ResearchConceptsStandard of carePrimary careTeam medicineHealth equityCancer survivorship careLarge multidisciplinary teamNumber of survivorsSurvivorship careHealth care administrationLate effectsCancer survivorshipComplex careHealthy behaviorsMultidisciplinary teamPatient careSurvivors' needsOncologyCareKnowledge deficitsCare administrationPatientsSubspecialistsDiagnosisWorkforce shortagesMedicineEstablishing Goals of Care
Choi A, Sanft T. Establishing Goals of Care. Medical Clinics Of North America 2022, 106: 653-662. PMID: 35725231, DOI: 10.1016/j.mcna.2022.01.007.Peer-Reviewed Original Research
2020
Education needed to improve antimicrobial use during end-of-life care of older adults with advanced cancer: A cross-sectional survey
Datta R, Topal J, McManus D, Sanft T, Dembry LM, Morrison LJ, Quagliarello V, Juthani-Mehta M. Education needed to improve antimicrobial use during end-of-life care of older adults with advanced cancer: A cross-sectional survey. Palliative Medicine 2020, 35: 236-241. PMID: 32928066, DOI: 10.1177/0269216320956811.Peer-Reviewed Original ResearchConceptsEscalation of careAdvance care planningLife careAdvanced cancerCross-sectional surveyIntravenous antimicrobialsOlder adultsAntimicrobial useCare planningSingle-center cross-sectional surveyEducational interventionAdvance care plansRole of antimicrobialsClinical deteriorationPercent of respondentsAdverse eventsOral antimicrobialsMedicine subspecialistsCare plansInpatient medicineCareCancerPatientsAdultsSubspecialists
2019
A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making
Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management 2019, 8: bmt22. DOI: 10.2217/bmt-2019-0001.Peer-Reviewed Original Research
2018
Defining the patient experience in medical oncology.
Odai-Afotey A, Kliss A, Hafler J, Sanft T. Defining the patient experience in medical oncology. Journal Of Clinical Oncology 2018, 36: 167-167. DOI: 10.1200/jco.2018.36.30_suppl.167.Peer-Reviewed Original ResearchQuality of carePatient experiencePatient satisfactionPatients' perceptionsYale-New Haven HospitalPhysician emotional supportCoordination of careHigh patient satisfactionPositive patient satisfactionNew Haven HospitalImproved health outcomesQuality of lifePhysician attentivenessMixed-method study designMedical oncologyTreatment adherencePatient interviewsHospital experiencePhysician communicationElicit patientPractice physiciansPatientsPatient needsHealth outcomesMeeting patients84 Psychosocial Consequences and Lifestyle Interventions
Mehra K, Berkowitz A, Sanft T. 84 Psychosocial Consequences and Lifestyle Interventions. 2018, 1039-1048.e4. DOI: 10.1016/b978-0-323-35955-9.00084-2.Peer-Reviewed Original ResearchLifestyle interventionBreast cancerBreast cancer patientsBreast cancer riskLives of patientsLifestyle factorsCancer patientsInterventional studyCancer riskPsychosocial interventionsPsychosocial consequencesSignificant distressPatientsCancerInterventionOverview of optionsDiseaseDistressRiskPainPrognosisArea of investigationDiagnosisSurvivorsWomen
2016
Recent Updates in the Management of Triple Negative Breast Cancer
Sanft T, Moran M. Recent Updates in the Management of Triple Negative Breast Cancer. TouchREVIEWS In Oncology & Haematology 2016, 12: 36. DOI: 10.17925/ohr.2016.12.01.36.Peer-Reviewed Original ResearchTriple-negative breast cancerNegative breast cancerBreast cancerLocoregional treatment optionsComplete pathologic responseNeoadjuvant chemotherapyPathologic responseResidual diseaseTreatment optionsAggressive subtypeNew agentsCancerDruggable targetsDisease biologyRecent updatesFurther researchChemotherapyPatientsTherapySubtypesDisease
2015
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.Peer-Reviewed Original Research
2014
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.
Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.Peer-Reviewed Original Research